Effects of organic extracts and their different fractions of five Bangladeshi plants on  thrombolysis by unknown
Emran et al. BMC Complementary and Alternative Medicine  (2015) 15:128 
DOI 10.1186/s12906-015-0643-2RESEARCH ARTICLE Open AccessEffects of organic extracts and their different
fractions of five Bangladeshi plants on
in vitro thrombolysis
Talha Bin Emran1,2*, Md Atiar Rahman2, Mir Muhammad Nasir Uddin3, Md Mominur Rahman4, Md Zia Uddin1,
Raju Dash1 and Chadny Layzu2Abstract
Background: The increasingly high incidence of ischemic stroke caused by thrombosis of the arterial vessels is one
of the major factors that threaten people’s health and lives in the world. The present treatments for thrombosis are
still unsatisfactory. Herbal preparations have been used since ancient times for the treatment of several diseases.
The aim of this study was to investigate whether herbal preparations possess thrombolytic activity or not.
Methods: An in vitro thrombolytic model was used to check the clot lysis effect of the crude extracts and fractions
of five Bangladeshi plant viz., Trema orientalis L., Bacopa monnieri L., Capsicum frutescens L., Brassica oleracea L. and
Urena sinuata L. using streptokinase as a positive control and water as a negative control. Briefly, venous blood
drawn from twenty healthy volunteers was allowed to form clots which were weighed and treated with the test
plant materials to disrupt the clots. Weight of clot after and before treatment provided a percentage of clot lysis.
Results: Using an in vitro thrombolytic model, different fractions of five Bangladeshi medicinal plants namely
T. orientalis, B. monnieri, C. frutescens, B. oleracea and U. sinuata showed various range of clot lysis activity. Chloroform
fractions of T. orientalis, B. monnieri, C. frutescens, B. oleracea and U. sinuata showed highest significant (P < 0.05 and
P < 0.001) clot lysis activity viz., 46.44 ± 2.44%, 48.39 ± 10.12%, 36.87 ± 1.27%, 30.24 ± 0.95% and 47.89 ± 6.83% respectively
compared with positive control standard streptokinase (80.77 ± 1.12%) and negative control sterile distilled water
(5.69 ± 3.09%). Other fractions showed moderate to low clot lysis activity. Order of clot lysis activity was found to be:
Streptokinase > Chloroform fractions > Methanol (crude) extract > Hydro-methanol fractions > Ethyl acetate fractions >
n-hexane fractions >Water.
Conclusions: Our study suggests that thrombolytic activity of T. orientalis, B. monnieri and U. sinuata could be
considered as very promising and beneficial for the Bangladeshi traditional medicine. Lower effects of other extracts
might suggest the lack of bio-active components and/or insufficient quantities in the extract. In vivo clot dissolving
property and active component(s) of T. orientalis and B. monnieri for clot lysis could lead the plants for their therapeutic
uses. However, further work will establish whether or not, chloroform soluble phytochemicals from these plants could
be incorporated as a thrombolytic agent for the improvement of the patients suffering from atherothrombotic diseases.
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Thrombosis, the blockage of blood vessels with clots,
can lead to acute myocardial infarction and ischemic
stroke, the leading causes of death. Other than surgical
interventions to remove or by pass the blockage, or the
generation of collateral vessels to provide a new blood
supply, the only treatment available is the administration
of thrombolytic agents to dissolve the blood clot [1].
Thrombolytic agents that comprise tissue plasminogen
activator (t-PA), urokinase (UK), streptokinase (SK) etc.
are used all over the world for the treatment of these
diseases. As compared to other thrombolytic drugs in
India, Bangladesh and other developing countries, SK
and UK are extensively used due to lower price [2,3]. All
available thrombolytic agents still have significant short-
comings, including the need for large doses to be maxi-
mally effective, limited fibrin specificity and bleeding
tendency. Because of the shortcomings of the available
thrombolytic drugs, attempts are underway to develop
improved recombinant variants of these drugs [4,5].
Day-by-day the context, concept and methods of the
uses of natural products in treatment of human have
undergone remarkable changes. Such changes occurred
due to the fact that natural medicine or traditional me-
dicine made a revolutionary come-back with renewed
strength and vigour to play a more significant role in the
management of human health [6]. Significant efforts
have been concentrating towards the discovery and de-
velopment of natural products from various plant and
animal sources which have anti-platelet [7,8], anti-
coagulant [9,10], anti-thrombotic [11] and thrombolytic
activity. Epidemiologic studies have provided evidence
that foods with experimentally proved anti-thrombotic
effect could reduce risk of thrombosis [12]. Some plants
or plant parts showing thrombolytic activity have also
been reported [13]. Trema orientalis (Chikan), Bacopa
monnieri (Brahmi), Capsicum frutescens (Lanka-marich or
Marich), Brassica oleracea (Cauliflower), Urena sinuata
(Kunjia, Kungooya) are native to Bangladesh. They are used
as traditional medicines for cardiac diseases and blood puri-
fication. Trema orientalis has recently been focused due
to therapeutic activity on hypoglycemic, analgesic, anti-
inflammatory, anti-plasmodial, diuretic activity, laxativity,
anti-convulsant, anti-helmintic, anti-sickling, antioxidant
and antibacterial activity [14]. Bacopa monnieri possesses
neuroprotective properties, nootropic activity with thera-
peutic implications for patients with memory loss [15]. The
fruit of Capsicum frutescens is a cardiovascular stimulant,
Capsicum assists in lowering blood pressure and breaking
down cholesterol build-up [16]. Brassica vegetables possess
high levels of antioxidant metabolites associated with bene-
ficial health effects including vitamins, carotenoids, antho-
cyanins, soluble sugars and phenolics [16]. The biological
investigation of Urena sinuata has not been subjected yet.This study aims to investigate the different organic ex-
tracts of the aforementioned five Bangladeshi medicinal
plants viz., Trema orientalis (T. orientalis), Bacopa mon-
nieri (B. monnieri), Capsicum frutescens (C. frutescens),
Brassica oleracea (B. oleracea), Urena sinuata (U. sinuata)
for their clot lysis (thrombolytic activity) by using in vitro
models.
Methods
Plant collection and identification
Leaf of T. orientalis (Accession No. 30816), leaf of B.
monnieri (Accession No. 32216), fruits of C. frutescens
(Accession No. 33018), fruits of B. oleracea (Accession
No. 30072) and leaf of U. sinuata (Accession No. 36155)
were collected from different parts of Chittagong region
(Chakaria Upazila, University of Chittagong campus and
Hill tracts area of Chittagong, Bangladesh). The plants
were identified by Bangladesh Forest Research Institute
(BFRI), Chittagong-4211, Bangladesh. The sample speci-
mens of the identified plants have been preserved in the na-
tional herbarium with the mentioned accession numbers.
Extract preparation and solvent-solvent partitioning
Plant materials were dried and ground (Moulinex Blender
CK-243, Moulinex, France) into powder (50–80 mesh,
450 g approx.) to soak in 2.5 L of methanol for 14 days at
room temperature (23 ± 0.5°C). Filtrate obtained through
cheesecloth and Whatman filter paper No. 1 was concen-
trated under reduced pressure at the temperature below
45°C using rotary evaporator (Buchi Rotavapor R-200,
Germany). The solvent was completely removed by using
rotary evaporator (Buchi Rotavapor R-200, Germany) and
obtained T. orientalis 7.74 g (yield 3.87% w/w), B. mon-
nieri 18 g (yield 3.60% w/w), C. frutescens 23 g (yield
5.50% w/w), B. oleracea 48 g (yield 6.40% w/w) and
U. sinuata 16 g (yield 3.4% w/w) of dried crude extracts.
All of the extracts were placed in glass Petri dishes
(90 × 15 mm, Pyrex, Germany).
Crude extracts were undertaken for solvent-solvent
partitioning by using the protocol designed by Kupchan
and Tsou [17] and modified version of Wagenen et al.
[17]. The crude extract (5 g) was triturated by dissolving
in 10% aqueous methanol (methanol: water; 9:1 v/v) to
make the mother solution which was successively parti-
tioned by four solvents such as n-hexane, chloroform,
ethyl acetate and hydro-methanol in order of increasing
polarity by using separating funnel (Figure 1). Physical
appearances of the fractions and their quantity after par-
titioning are shown in Table 1. Resulting fractions of
each plant extract were dried by evaporating respective
solvent using rotary evaporator. All extracts were stored
at 4°C in air tight containers till further analysis [18]. A
100 mg each of the extracts was suspended in 10 mL
distilled water and the suspension was shaken vigorously
Figure 1 Schematic representation of the modified Kupchan partitioning of methanol crude extracts of T. orientalis, B. monnieri, C. frutescens,
B. oleracea and U. sinuata. The crude extract was (5 g) was triturated by dissolved in 10% aqueous methanol (methanol: water; 9:1 v/v) to make the
mother solution which was partitioned off successively by four solvents such as n-hexane (HX: 820 mg), chloroform (CH: 550 mg), ethyl acetate
(EAT: 665 mg) and hydro-methanol (HM: 1.5 g) in order of increasing polarity by using separating funnel.
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and decanted to remove the soluble supernatant, which
was filtered through a 0.22-μm syringe filter. A 100 μL
of this aqueous preparation was added to the microcen-
trifuge tubes containing the clots to check thrombolytic
activity [13].
Chemicals and reagents
To the commercially available lyophilized SK vial (Polamin
Werk GmbH, Herdecke, Germany) of 15,00,000 I.U.,
5 mL sterile distilled water was added and mixed properly.
This suspension was used as a stock from which 100 μL
(30,000 I.U.) was used for in vitro thrombolysis.Blood specimen
Whole blood (vein, 4 mL) was drawn from healthy human
volunteers (n = 20) without a history of oral contraceptive
or anticoagulant therapy using a protocol approved by the
Institutional Ethics Committee of Chittagong Medical
College, Chittagong-4218, Bangladesh. An earlier consent,
approval number ME-CMC 2012/05, was taken from the
Chittagong Medical College, Chittagong-4218, for collec-
tion of blood samples from human volunteers. Blood col-
lection and preservation were conducted by Dr. Shafiqul
Islam (Pathologist, Premium Hospital Pvt. Ltd., Chittagong).
A 500 μL of blood was transferred to each of the eight pre-
viously weighed microcentrifuge tubes to form clots.
Table 1 Four different fractions of T. orientalis, B. monnieri, C. frutescens, B. oleracea and U. sinuata obtained after
Kupchan-partitioning of the crude methanol extract
Plants Extract/Fractions Amount (g/mg) Yield (% w/w) Physical appearance
Trema orientalis Methanol (crude) 7.74 g 3.87 Greenish sticky mass
Chloroform 550 mg 0.03 Red muddy structure
n-hexane 820 mg 0.06 Deep green gummy mass
Hydro-methanol 1.5 g 0.28 Ash like sticky mass
Ethyl acetate 665 mg 0.05 Blackish sticky mass
Bacopa monnieri Methanol (crude) 18 g 3.60 Greenish sticky mass
Chloroform 2.25 g 0.45 Blackish sticky mass
n-hexane 0.55 g 0.11 Deep green gummy mass
Hydro-methanol 2.10 g 0.89 Grayish structure with presence
of small needle shaped crystals
Ethyl acetate 1.20 g 0.39 Deep red muddy structure
Capsicum frutiescens Methanol (crude) 23 g 5.50 Greenish sticky mass
Chloroform 920 mg 0.99 Green gummy mass
n-hexane 80 mg 0.09 Blackish sticky mass
Hydro-methanol 639 mg 0.10 Ash like sticky mass
Ethyl acetate 90 mg 0.06 Deep green gummy mass
Brassica oleracea Methanol (crude) 48 g 6.40 Greenish sticky mass
Chloroform 1.02 g 0.68 Red muddy structure
n-hexane 357 mg 0.11 Deep green gummy mass
Hydro-methanol 439 mg 0.14 Blackish sticky mass
Ethyl acetate 120 mg 0.09 Grayish structure
Urena sinuata Methanol (crude) 16 g 3.4 Greenish sticky mass
Chloroform 484 mg 0.11 Red muddy structure
n-hexane 732 mg 0.29 Deep green gummy mass
Hydro-methanol 846 mg 0.42 Grayish structure
Ethyl acetate 234 mg 0.10 Blackish sticky mass
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The volunteer donors were supplied a consent form
which informed the title of the research project, name
and detail contact of investigators as well as purpose of
the research. Description of the research mentioning
step-by-step brief of the proposed research, inclusion
and exclusion criteria of the donors, whether donors will
receive any therapy or not, volume of blood to be taken,
possible discomfort of the puncture sites, time required
for the blood sampling. Explanation was made on if fu-
ture use of the research data beyond the current study is
anticipated, whether this is a focus group if so the prin-
cipal investigator should put a procedure in place in
which the researchers caution people about the limit on
confidentiality. Access to research information regarding
who would have access to the collected sample, informa-
tion regarding retention of sample and schedules for
their disposal were also detailed. It was indicated to the
consent form that the volunteers might refuse to donate
blood at any time. Donor whether could withdraw hissample data was disclosed. The sample was restricted for
that individual study not for future research projects was
presented in the consent form. Potential harm, injuries,
discomforts or inconvenience associated with donors in
this study was added as informed consent statement. If
there was known harm to the donors, the potential
harm, current knowledge regarding the probability of
the occurrence of the harm, clinical importance of the
harm; and any relevant knowledge regarding the prob-
ability of reversibility; for example the possibility of
bruising or swelling while giving blood, or some other
discomforts at the site where blood is drawn and that
there might be minimal chance of infection, and that
these discomforts were brief and transient were also
added. Potential benefits of the donors, not directly, but
the society in general or individuals with a similar con-
dition might benefit from the results of this study was
explained. Treatment alternative and possibility of the re-
search was described. Confidentiality statement was in-
cluded in the consent form in the way that “confidentiality
Table 2 Effect of herbal extracts and their different
fractions on in vitro clot lysis










- 80.77 ± 1.12** <0.001
*
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identity of the participant will be released or published
without consent unless required by law of states. The legal
obligation includes a number of circumstances, such as
suspected child abuse and infectious disease, expression of
suicidal ideas where research documents are ordered to be
produced by a court of law and where researchers are
obliged to report to the appropriate authorities. In those
rare instances where it will not be possible to assure
complete confidentiality”, the limits on this obligation
were carefully explained. Reimbursement issue was also
mentioned whether the donors or their parents may be
offered money for reasonable out-of-pocket expenses for
example, transportation costs, meals, etc. Finally detail
contact (name, area code and phone number) of investiga-
tors was provided in case of any questions of the donors
about this study. The consent form was concluded with
major questions on above disclosures in Yes/NO form
followed by the signature (with date) of the donor.Water
(−ve control)
- 5.69 ± 3.09 <0.05
Trema orientalis Methanol (crude) 47.88 ± 6.12** <0.001
Chloroform 46.44 ± 2.44** <0.001
n-hexane 15.37 ± 0.29
Hydro-methanol 45.78 ± 3.32** <0.001
Ethyl acetate 43.29 ± 2.98** <0.001
Bacopa monnieri Methanol (crude) 43.38 ± 8.69** <0.001
Chloroform 48.39 ± 10.12** < 0.001
n-hexane 32.88 ± 10.72* < 0.05
Hydro-methanol 30.73 ± 1.13* < 0.05
Ethyl acetate 27.68 ± 1.34* < 0.05
Capsicum
frutiescens
Methanol (crude) 27.96 ± 0.50* < 0.05
Chloroform 36.87 ± 1.27* < 0.05
n-hexane 11.23 ± 1.29
Hydro-methanol 40.29 ± 1.26** < 0.001
Ethyl acetate 19.82 ± 0.49
Brassica oleracea Methanol (crude) 34.96 ± 4.60* < 0.05
Chloroform 30.24 ± 0.95* < 0.05
n-hexane 18.30 ± 3.55
Hydro-methanol 43.70 ± 1.97** < 0.001
Ethyl acetate 15.29 ± 11.29
Urena sinuata Methanol (crude) 39.30 ± 2.87* < 0.05Clot lysis
Experiments for clot lysis were carried as reported pre-
viously [19]. Briefly, 4 mL venous blood drawn from the
healthy volunteers was distributed in eight different pre-
weighed sterile microcentrifuge tubes (0.5 mL/tube) and
incubated at 37°C for 45 minutes. After clot formation,
serum was completely removed without disturbing the
clot and each tube having clot was again weighed to
determine the clot weight (clot weight = weight of clot
containing tube – weight of tube alone). To each micro-
centrifuge tube containing pre-weighed clot, 100 μL of
different organic extracts of the five plants (T. orientalis,
B. monnieri, C. frutescens, B. oleracea and U. sinuata)
were added separately. As a positive control, 100 μL of
SK and as a negative non-thrombolytic control, 100 μL
of distilled water were separately added to the control
tubes numbered. All the tubes were then incubated at
37°C for 90 minutes and observed for clot lysis. After
incubation, released fluid was removed and tubes were
again weighed to observe the difference in weight after
clot disruption. Difference obtained in weight taken be-
fore and after clot lysis was expressed as percentage of
clot lysis. The experiment was repeated with the blood
samples of the twenty (20) healthy volunteers.Chloroform 47.89 ± 6.83** < 0.001
n-hexane 26.58 ± 10.27* < 0.05
Hydro-methanol 29.51 ± 3.62* < 0.05
Ethyl acetate 38.29 ± 2.18* < 0.05
Values are mean ± SD, (n = 5); *P < 0.05, **P < 0.001, Dunnet test as compared
to control (positive and negative). Statistical representation of the effective
clot lysis percentage by herbal preparations, positive thrombolytic control
(Streptokinase) and negative control (sterile distilled water) processed by
paired t-test analysis (Dunnet test). Bold text indicates the highest clot lytic
activity of chloroform extract of Bacopa monnieri.Statistical analysis
The significance between % clot lysis by SK and plant
extracts was tested by the paired t-test analysis using the
software SPSS, version 18.0 (SPSS for Windows, Version
18.0, IBM Corporation, New York, USA). Data are
expressed as mean ± standard deviation. The mean dif-
ference between positive and negative control was con-
sidered significant at P values < 0.05 and 0.001.Results
Addition of 100 μL SK (positive control) to the clots
along with 90 minutes of incubation at 37°C, showed
80.77 ± 1.12% clot lysis. Sterile distilled water (negative
control) treated-clots showed only 5.69 ± 3.09% clot lysis
which is very negligible. The mean differences in clot
lysis percentage between positive and negative control
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tively). Chloroform fractions of B. monnieri showed the
highest (48.39%) significant (P values < 0.001) clot lysis
activity among the other extracts. Chloroform fractions
of U. sinuata (47.89%) and T. orientalis (46.44%) also
gave significant (P values < 0.001) clot lysis which is al-
most similar to that of B. monnieri chloroform fractions.
Chloroform fractions of C. frutiescens and B. oleracea
have the moderate but significant (P values < 0.05) clot
lysis activity and the values were respectively 36.87% and
30.24%. However, hydro-methanol fractions of T. orien-
talis, C. frutiescens and B. oleracea have significant clot
lysis activity viz. 45.78%, 43.70%, 40.29% respectively
(P values < 0.001). n-hexane fractions of only B. monnieri
showed moderate also significant (P values < 0.05) clot
lysis 32.88% whereas ethyl acetate fractions of T. orientalis
(43.29%) and U. sinuata (38.29%) (P values < 0.001 and
0.05 respectively) had significant clot lysis activity. Other
ethyl acetate fractions showed very lower clot lyses which
were insignificant compared to negative control. Crude
methanol extract of all plants except C. frutiescens had
significant (P values < 0.001 and 0.05) clot lysis activity.
Percent clot lysis obtained after treating the clots with dif-
ferent organic extracts and appropriate controls is shown
in Table 2 and represent in Figure 2.Figure 2 Clot lysis by streptokinase, water, various organic extracts and the
from blood of normal individuals. Maximum clot lysis (80.77 ± 1.12%) was o
chloroform fractions of T. orientalis, B. monnieri, C. frutescens, B. oleracea and
lysis activity viz., 46.44 ± 2.44%, 48.39 ± 10.12%, 36.87 ± 1.27%, 30.24 ± 0.95%
control) showed 5.69 ± 3.09% clot lysis. Values are mean ± SD, (n = 5); *P < 0
negative). Data were processed by paired t-test analysis by using SPSS for wDiscussion
Numbers of pharmaceuticals approved by the Food and
Drug Administration (FDA) currently have origins to
plant sources. Based on the reported immunomodula-
tory effects, the most important role for plant-derived
compounds has emerged in recent times and has led to
the precise scientific examination to determine efficacy
and safety [20,21]. A number of plants source especially
several fruits and vegetables have been studied for their
supplements having anti-coagulant, anti-platelet and fibri-
nolytic activity and there is evidence that consuming such
food leads to prevention of coronary events and stroke
[22-24]. There are several thrombolytic drugs obtained
from various sources. In our present study, four different
extracts of five diverse plants showed the thrombolytic
activity among which the crude extracts and fractions of
T. orientalis and B. monnieri, had the significant activity
than the other plants. B. oleracea and U. sinuata have
moderate thrombolytic activity. The maximum clot lysis
activity was mostly observed in chloroform fractions that
mean chloroform soluble compounds are mainly res-
ponsible for the thrombolytic activity. Hydro-methanol
fractions are next to the chloroform fractions in clot lysis
effect. It is evident that there are bacterial contaminants of
plants which have plasminogen receptors that bindir different fractions. Effects of drugs on dissolution of clots prepared
bserved in clot treated with streptokinase (SK). Among herbal drugs
U. sinuata showed highest significant (P < 0.05 and P < 0.001) clot
and 47.89 ± 6.83% respectively. Sterile distilled water (as a negative
.05, **P < 0.001, Dunnet test as compared to control (positive and
indows, version 18.0.
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tivated to plasmin, which could lead to fibrinolysis [25] al-
though some other plants exert their thrombolytic or
fibrinolytic effects via their content of certain fibrinolytic
proteases enzymes. However, bacterial plasminogen acti-
vator: staphylokinase, streptokinase, act as cofactor mole-
cules that contribute to exosite formation and enhance
the substrate presentation to the enzyme. Staphylokinase
activates plasminogen to dissolve clots, also destroys
the extra-cellular matrix and fibrin fibers that hold
cells together [26,27]. Coincidentally, crude methanol ex-
tract of T. orientalis showed antibacterial activity against
Staphylococcus aureus, Staphylococcus epidermidis [28].
B. monnieri was also found to have very strong antibacte-
rial effect against Staphylococcus aureus [29]. Koffi-Nevry
et al. [30] noticed very promising effect of C. frutescens
methanol extracts against Staphyloccus aureus. Rahman
et al. [13] has also linked the thrombolytic effects of plant
materials with the anti-staphylococcal effects although
some of these plants/plant products are modified further
in order to use as thrombolytic drugs which are more
site specific and effective [31]. Sibi et al. [32] have also
determined the in vitro antibacterial activities of Broccoli
(B. oleracea) against food borne bacteria. Individual chem-
ical component-activity relationship, which can explore
the other new clue for the observed thrombolytic effects
of these plants, will be the next step of the research
follow-up of our continuous study.
Conclusion
We have described the thrombolytic activity of T. orientalis,
B. monnieri, C. frutescens, B. oleracea and U. sinuata, which
are beneficial in the Bangladeshi traditional medicine, vali-
dated in this study by in vitro blood clots lysis activity of
their different organic fractions. However, T. orientalis
and B. monnieri showed the promising thrombolytic ef-
fects to be studied further for therapeutic applications.
Identification of their bioactive components and a dose–
response relationship study in in vivo model is claimed to
use these indigenous sources for pharmaceutical pre-
parations. Chloroform soluble phytochemicals from these
plants will be focused especially whether the fractions
could account for the incorporation as a thrombolytic
agent to the improvement of the patients suffering from
atherothrombotic diseases.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
TBE and RD designed the study, collected the data, performed data analysis
and interpretation and wrote the manuscript. MAR has formatted, revised
and reorganized the manuscript along with data presentation and interpretation.
MMNU, MZU and CL participated in experiments, data collection, literature
search and manuscript preparation. MMR has provided assistance in taxonomical
identification and collections of voucher specimen’s numbers for all the plants.
All authors read and approved the final version of the manuscript.Acknowledgements
We all authors are grateful to Bangladesh Forest Research Institute (BFRI),
Chittagong-4211, Bangladesh for identifying the plant samples. We are
pleased to Dr. Shafiqul Islam Pathologist, Premium Hospital Pvt. Ltd. for his
continuous support in this experiment. The authors are also gratified to
Prof. Dr. S. K. S. Hazari, Vice-Chancellor, BGC Trust University Bangladesh,
for providing facilities to carry out the experiment at the Department of
Pharmacy, BGC Trust University Bangladesh.
Author details
1Department of Pharmacy, BGC Trust University Bangladesh, Chittagong
4000, Bangladesh. 2Department of Biochemistry and Molecular Biology,
University of Chittagong, Chittagong 4331, Bangladesh. 3Department of
Pharmacy, University of Chittagong, Chittagong 4331, Bangladesh.
4Department of Pharmacy, International Islamic University Chittagong,
Chittagong 4203, Bangladesh.
Received: 3 October 2014 Accepted: 9 April 2015References
1. Kunamneni A, Abdelghani TT, Ellaiah P. Streptokinase-the drug of choice for
thrombolytic therapy. J Thromb Thrombolysis. 2007;23(1):9–23.
2. Mucklow JC. Thrombolytic treatment: Streptokinase is more economical
than alteplase. BMJ. 1995;311(7018):1506–10.
3. Collen D. Coronary thrombolysis: streptokinase or recombinant tissue-type
plasminogen activator? Ann Intern Med. 1990;112(7):529–38.
4. Sumi H, Hamada H, Nakanishi K, Hiratani H. Enhancement of the fibrinolytic
activity in plasma by oral administration of nattokinase. Acta Haematol.
1990;84(3):139–43.
5. Furie B, Furie BC. Mechanisms of thrombus formation. N Engl J Med.
2008;359(9):938–49.
6. Gesler WM. Therapeutic landscapes: medical issues in light of the new
cultural geography. Soc Sci Med. 1992;34(7):735–46.
7. Demrow HS, Slane PR, Folts JD. Administration of wine and grape juice
inhibits in vivo platelet activity and thrombosis in stenosed canine coronary
arteries. Circulation. 1995;91(4):1182–8.
8. Briggs WH, Folts JD, Osman HE, Goldman IL. Administration of raw onion
inhibits platelet-mediated thrombosis in dogs. J Nutr. 2001;131(10):2619–22.
9. Leta GC, Mourao PA, Tovar AM. Human venous and arterial glycosaminoglycans
have similar affinity for plasma low-density lipoproteins. Biochim Biophys Acta.
2002;24(3):243–53.
10. Li Z, Wang H, Li J, Zhang G, Gao C. Basic and clinical study on the
antithrombotic mechanism of glycosaminoglycan extracted from sea
cucumber. Chin Med J. 2000;113(8):706–11.
11. Rajapakse N, Jung WK, Mendis E, Moon SH, Kim SK. A novel anticoagulant
purified from fish protein hydrolysate inhibits factor XIIa and platelet
aggregation. Life Sci. 2005;76(22):2607–19.
12. Vietti Violi N, Fournier N, Duran R, Schmidt S, Bize P, Guiu B, et al. Acute
mesenteric vein thrombosis: factors associated with evolution to chronic
mesenteric vein thrombosis. AJR Am J Roentgenol. 2014;203(1):54–61.
13. Rahman MA, Sultana R, Emran TB, Islam MS, Chakma JS, Rashid HU, et al.
Effects of organic extracts of six Bangladeshi plants on in vitro thrombolysis
and cytotoxicity. BMC Complement Altern Med. 2013;13(25):1472–6882.
14. Adinortey MB, Galyuon IK, Asamoah NO. Trema orientalis Linn. Blume: A
potential for prospecting for drugs for various uses. Pharmacogn Rev.
2013;7(13):67–72.
15. Shinomol GK, Muralidhara, Bharath MM. Exploring the role of "Brahmi"
(Bocopa monnieri and Centella asiatica) in brain function and therapy.
Recent Pat Endocr Metab Immune Drug Discov. 2011;5(1):33–49.
16. Sotelo T, Cartea ME, Velasco P, Soengas P. Identification of antioxidant
capacity-related QTLs in Brassica oleracea. PLoS One. 2014;9(9):5–11.
17. Kupchan SM, Tsou G, Sigel CW. Datiscacin, a novel cytotoxic cucurbitacin
20-acetate from Datisca glomerata. J Org Chem. 1973;38(7):1420–1.
18. Bibi Y, Nisa S, Chaudhary FM, Zia M. Antibacterial activity of some selected
medicinal plants of Pakistan. BMC Complement Altern Med.
2011;11(52):1472–6882.
19. Prasad S, Kashyap RS, Deopujari JY, Purohit HJ, Taori GM, Daginawala HF.
Development of an in vitro model to study clot lysis activity of thrombolytic
drugs. Thromb J. 2006;4:14.
Emran et al. BMC Complementary and Alternative Medicine  (2015) 15:128 Page 8 of 820. Licciardi PV, Underwood JR. Plant-derived medicines: a novel class of
immunological adjuvants. Int Immunopharmacol. 2011;11(3):390–8.
21. Potterat O, Hamburger M. Drug discovery and development with
plant-derived compounds. Prog Drug Res. 2008;65(45):47–118.
22. Torres-Urrutia C, Guzman L, Schmeda-Hirschmann G, Moore-Carrasco R,
Alarcon M, Astudillo L, et al. Anti-platelet, anti-coagulant and fibrinolytic
activity in vitro of extracts from selected fruits and vegetables. Blood Coagul
Fibrinolysis. 2011;22(3):197–205.
23. Bazzano LA, He J, Ogden LG, Loria CM, Vupputuri S, Myers L, et al. Fruit and
vegetable intake and risk of cardiovascular disease in US adults: the first
national health and nutrition examination survey epidemiologic follow-up
study. Am J Clin Nutr. 2002;76(1):93–9.
24. Liu S, Manson JE, Lee IM, Cole SR, Hennekens CH, Willett WC, et al. Fruit and
vegetable intake and risk of cardiovascular disease: the Women's Health
Study. Am J Clin Nutr. 2000;72(4):922–8.
25. Verstraete M. Third-generation thrombolytic drugs. Am J Med.
2000;109(1):52–8.
26. Pantzar M, Ljungh A, Wadstrom T. Plasminogen binding and activation at
the surface of Helicobacter pylori CCUG 17874. Infect Immun.
1998;66(10):4976–80.
27. Parry MA, Zhang XC, Bode I. Molecular mechanisms of plasminogen
activation: bacterial cofactors provide clues. Trends Biochem Sci.
2000;25(2):53–9.
28. Sherry S, Marder VJ. Streptokinase and recombinant tissue plasminogen
activator (rt-PA) are equally effective in treating acute myocardial infarction.
Ann Intern Med. 1991;114(5):417–23.
29. Uddin SR. Antioxidant and antibacterial activities of Trema orientalis Linn: an
indigenous medicinal plant of indian subcontinent. Ori Pharm Exp Med.
2008;8(4):395–9.
30. Mathur A, Verma SK, Purohit R, Singh SK, Mathur D, Prasad GBKS, et al.
Pharmacological investigation of Bacopa monnieri on the basis of
antioxidant, antimicrobial and anti-inflammatory properties. J Chem Pharm
Res. 2010;2(6):191–8.
31. Koffi-Nevry R, Kouassi KC, Nanga ZY, Koussémon M, Loukou GY. Antibacterial
activity of two bell pepper extracts: Capsicum annuum L. and Capsicum
frutescens L. Int J Food Prop. 2012;15(5):961–71.
32. Sibi G, Shukla A, Dhananjaya K, Ravikumar KR, Mallesha H. In vitro
antibacterial activities of Broccoli (Brassica oleracea L. var italica) against
food borne bacteria. J Appl Pharma Sci. 2013;3(5):100–3.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
